supplementary materials: Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis.docx

supplementary materials: Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis

NIAID Data Ecosystem00

Lorlatinib in patients with ALK -positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study

This post-approval study was conducted to confirm efficacy of lorlatinib in anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) that progressed on one prior second-

NIAID Data Ecosystem20

Supplementary Material for: Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Background: Crizotinib and alectinib are the two most commonly used anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive non-small cell lung cancer (NSCLC). We compared their antitumor efficac

Figshare2021-12-14 更新10